Syndax Pharmaceuticals Q2 Earnings Call Highlights

Impact · against what's priced in

Syndax shares are poised for growth driven by stronger-than-expected peak revenue targets for Revuforj and high untapped penetration in NPM1-mutated AML. The company also establishes two binary catalysts for Niktimvo in Q4, expanding its potential addressable market.

SNDX+0.70

No priced-in read yet

In context

Management raised the peak US net revenue target for Revuforj to over $2 billion contingent on frontline AML indications and highlighted that less than 15% of 4,500 annual NPM1 patients have received a menin inhibitor.

Read from the article alone

• revenue growth▲3%
• earnings
• INCY
• SNDX
• biopharma
• cancer treatment
• clinical trials
• drug pipeline
• leukemia